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Gender-specific changes in 
energy metabolism and protein 
degradation as major pathways 
affected in livers of mice treated 
with ibuprofen
Shuchita Tiwari1, Manish Mishra1, Michelle R. Salemi2, Brett S. Phinney2, Joanne L. Newens1 &  
Aldrin V. Gomes  1,3*
Ibuprofen, an inhibitor of prostanoid biosynthesis, is a common pharmacological agent used for 
the management of pain, inflammation and fever. However, the chronic use of ibuprofen at high 
doses is associated with increased risk for cardiovascular, renal, gastrointestinal and liver injuries. 
The underlying mechanisms of ibuprofen-mediated effects on liver remain unclear. To determine 
the mechanisms and signaling pathways affected by ibuprofen (100 mg/kg/day for seven days), we 
performed proteomic profiling of male mice liver with quantitative liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using ten-plex tandem mass tag (TMT) labeling. More than 300 proteins were 
significantly altered between the control and ibuprofen-treated groups. The data suggests that several 
major pathways including (1) energy metabolism, (2) protein degradation, (3) fatty acid metabolism 
and (4) antioxidant system are altered in livers from ibuprofen treated mice. Independent validation 
of protein changes in energy metabolism and the antioxidant system was carried out by Western 
blotting and showed sex-related differences. Proteasome and immunoproteasome activity/expression 
assays showed ibuprofen induced gender-specific proteasome and immunoproteasome dysfunction in 
liver. The study observed multifactorial gender-specific ibuprofen-mediated effects on mice liver and 
suggests that males and females are affected differently by ibuprofen.
Ibuprofen, a propionic acid derivative, is the most common over-the-counter nonsteroidal anti-inflammatory 
(NSAID) drug used to treat fever, pain, inflammation and many other disorders1. It has been included as a major 
medicine in the Essential Drugs List of the World Health Organization2. Ibuprofen at low over-the-counter 
doses (800–1200 mg/day) is used to treat muscular aches, backaches, toothaches, and fever. At higher doses 
(1800–2400 mg/day), ibuprofen is prescribed for the treatment of chronic conditions such as osteoarthritis, 
rheumatoid arthritis, and ankylosing spondylitis3. Ibuprofen is a non-selective inhibitor of the cyclo-oxygenase 
(COX) isozymes COX-1 and COX-2 that converts arachidonic acid into prostaglandins including thromboxane 
and prostacyclin1. The anti-inflammatory, antipyretic and analgesic effects of ibuprofen are mediated through 
the inhibition of prostaglandins E2 (PGE2) and I2 (PGI2) production by blocking COX activity1. Both PGE2 
and PGI2 are pro-inflammatory prostanoids that increase vascular permeability, promote leukocyte infiltra-
tion and increase edema formation4. The clearance of ibuprofen is mediated through oxidative metabolism 
by multiple cytochrome P450 (CYP) enzymes (CYP2C9, CYP2C8) to inactive primary metabolites including 
3-hydroxy-ibuprofen, carboxy ibuprofen and 2-hydroxy-ibuprofen5,6. Most of the ibuprofen is metabolized in 
liver, while only a small percentage of unchanged drug is excreted in the urine5.
The liver plays a key role in energy metabolism and is essential for whole body homeostasis via the regulation 
of glucose, lipid, and amino acid metabolism7. While various NSAIDs, including ibuprofen are considered safe 
to sell without prescriptions, they have the potential to cause adverse side effects. Adverse reactions associated 
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with NSAIDs treatment can affect the gastrointestinal system, increase blood pressure and cause cardiac, renal 
and hepatic injuries8,9. Treatment with aspirin to a patient with pericarditis was reported to develop acute liver 
injury10. The long term administration (4 weeks) of aspirin and ibuprofen to rats increased mitochondrial num-
ber, altered liver mitochondria ultrastructure and increased the metabolic activity of the CYP450 enzymes11. 
Previous research in our laboratory has suggested that physiological concentrations of NSAIDs (diclofenac, 
naproxen and meclofenamate sodium) cause mitochondrial and proteasome dysfunction in cardiac tissue12,13.
To investigate the mechanisms by which ibuprofen affect mouse liver, a quantitative LC-MS/MS technique 
using tandem mass tag (TMT) labeling was carried out to measure whole liver proteome changes after short-term 
(7 days) treatment of ibuprofen (100 mg/kg/day). Although the mass spectrometry was initially carried out on 
livers from male mice, we hypothesized that ibuprofen would cause similar effects on livers from female mice. 
To determine if ibuprofen has the same effect in male and female mice, biological assays and Western blots were 
carried out on ibuprofen and vehicle treated mice. The amount of ibuprofen utilized in mice would be equivalent 
to a human taking approximately 486 mg/day, significantly less than the 1200 mg/day maximum over-the-counter 
dosage recommended. Ibuprofen at a moderate amount (100 mg/kg/day) affected more proteins and pathways in 
mice liver than expected, including glycolysis, protein degradation, fatty acid metabolism and antioxidant system. 
Biological assays and Western blotting exposed significant gender-specific differences in livers from ibuprofen 
treated males and females relative to their respective controls.
Materials and Methods
Animal studies. Aged matched male and female C57BL/6J mice were used for the study. The study protocol 
was approved by Institutional Animal Care and Use Committee (IACUC) of the University of California, Davis. 
Mice were maintained at controlled temperature and humidity and had free access to food and water. Methods 
used for all mice were performed in accordance with UC Davis IACUC guidelines and regulations. Ibuprofen 
was administered orally in drinking water at a concentration 100 mg/kg/day for seven days. The average water 
consumption by mice was measured to ensure that mice got the appropriate levels of ibuprofen. The ibuprofen 
dose used in this study was similar to the concentrations used in previous studies1,14,15. This dosage was chosen as 
it approximates to a human taking 486 mg/day which is between two to three dosages of 200 mg/day. In humans 
the recommended dosages of ibuprofen are 200 to 400 mg orally every 4 to 6 hours as needed with a maximum 
dose of 1200 mg/day for over-the-counter use. A 1200 mg/day ibuprofen dose (20 mg/kg/day, assuming an average 
human weight of 60 kg), would correspond to a treatment of 246.9 mg/kg/day in mice using the dose translation 
equation (Human equivalent dose (HED) = Animal Dose (mg/kg) × Animal Km (3 for mouse)/Human Km (37 
for human)16. The maximum human prescription dose (3200 mg/day) would correspond to a 658.4 mg/kg/day 
dose in mice. Hence, the amount of ibuprofen used in this study (100 mg/kg/day) would approximate to a mod-
erate daily dose of ibuprofen in humans. At the end of the study the mice were euthanized, and the livers were 
collected and quickly washed twice in ice-cold phosphate-buffered saline (PBS). The tissues were then frozen and 
pulverized in liquid nitrogen. The pulverized tissue was collected in clean microcentrifuge tubes and stored at 
−80 °C until needed.
LC-MS/MS using 10–plex TMT proteomics. Sample preparation. Pulverized liver tissue (20 mg aliquot) 
were homogenized in lysis buffer (8 M urea, 50 mM TEAB (triethyl ammonium bicarbonate), pH 8) followed by 
sonication (at level 5; three cycles for 10 sec with 30 sec wait in between on ice) to reduce sample viscosity. The 
lysate was centrifuged at 15,000 g for 15 minutes at 4 °C, and the supernatant was separated. The protein concen-
tration of the supernatant was measured using Bicinchoninic Acid (BCA) protein assay. 100 µg (100 µl) of protein 
sample was removed and 5 µl of the 200 mM TCEP (tris(2-carboxyethyl) phosphine) added and incubated at 
55 °C for 1 hr in a heat block. After that, 5 µl of 375 mM iodoacetamide was added to the sample and incubated for 
30 minutes sheltered from light at room temp. The samples were acetone precipitated using pre-chilled (−20 °C) 
6 volumes (~600 µL) of acetone overnight. Next day samples were centrifuged at 10,000 xg for 10 minutes at 4 °C, 
the supernatant was discarded, and pellet was air dried.
Digestion of protein samples. The acetone-precipitated protein pellet was resuspended in 100 µl of 50 mM ammo-
nium bicarbonate (NH4CO3). 2.5 µL of trypsin (i.e. 2.5 µg) per 100 µg of protein was added to each sample and 
were incubated overnight at 37 °C. The digested samples were lyophilized with a speedvac and resuspended in 
0.1% trifluoroacetic acid (TFA) and 5% acetonitrile.
TMT 10-plex peptide labeling. TMT label reagents were allowed to equilibrate to room temperature (RT) and 
anhydrous acetonitrile was added to each tube. 21.6 µL of the TMT label reagents were added to each 20 µg of 
samples and were incubated for 1 hr at RT. The reaction was quenched by adding 8 µL of 5% hydroxylamine to 
the labeled samples and were incubated for 30 minutes at RT. All TMT labeled samples were combined in equal 
amounts in a new tube (200 µg) and were run on Mass spec after fractionation.
TMT labeled samples were then reconstituted in 0.1% TFA and the pH adjusted to 2 with 10% TFA17. The 
combined sample (200 µg) was separated into 8 fractions by Pierce High pH Reverse-Phase Peptide Fractionation 
kit (Thermo Scientific) with an extra wash before separation to remove extra labels17. The eight fractions were 
dried almost to completion.
LC-MS/MS. LC separation was done on a Dionex Nano Ultimate 3000 (Thermo Scientific) with a Thermo 
Easy-Spray source17. The digested peptides were reconstituted in 2% acetonitrile/0.1% TFA and 5 µl of each sam-
ple was loaded onto a PepMap 100 Å 3U 75 µm × 20 mm reverse-phase trap where they were desalted online 
before being separated on a 100 Å 2U 50-micron × 150 mm PepMap EasySpray reverse-phase column17. Peptides 
were eluted using a 180-minute gradient of 0.1% formic acid (A) and 80% acetonitrile (B) with a flow rate of 
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200 nL/min. The separation gradient was run with 2% to 5% B over 1 minute, 5% to 10% B over 9 minutes, 10% 
to 20% B over for 27 minutes, 20% to 35% B over 10 minutes, 35% B to 99% B over 10 minutes, a 2 minute hold at 
99% B, and finally 99% B to 2% B held at 2% B for 5 minutes17.
MS3 synchronous precursor selection workflow. Mass spectra were collected on a Fusion Lumos mass spectrometer 
(Thermo Fisher Scientific) in a data-dependent MS3 synchronous precursor selection (SPS) method17. MS1 spectra 
were acquired in the Orbitrap, 120 K resolution, 50 ms max inject time, 5 ×105 max inject time. MS2 spectra were 
acquired in the linear ion trap with a 0.7 Da isolation window, CID fragmentation energy of 35%, turbo scan speed, 
50 ms max inject time, 1 ×104 automatic gain control (AGC) and maximum parallelizable time turned on17. MS2 ions 
were isolated in the ion trap and fragmented with a HCD energy of 65%. MS3 spectra were acquired in the orbitrap 
with a resolution of 50K and a scan range of 100–500 Da, 105 ms max inject time and 1 × 105 AGC17.
TMT data analysis (Quantitative data analysis). The use of 5 ibuprofen treated samples and 5 vehicle treated 
samples for the TMT 10 plex experiment animals and a [1.2]-fold cut-off was based on power analysis taking into 
account that isobaric-labeled LC-MS/MS quantitative measurements are known to be compressed by various 
factors. These factors include ratio compression and cause an underestimation of changes in relative abundance 
of proteins across samples18. This underestimation was ≥50% for other isobaric labeling-based experiments19. In 
these experiments a protein that was upregulated by 2.4 gave a measurement of only 1.219. As such the [1.2]-fold 
change for the TMT experiment was considered to be equivalent to a [1.5]-fold change. For power analysis (using 
online program https://www.stat.ubc.ca/rollin/stats/ssize/n2.html), when sigma (common standard deviation) 
was set at 25%, power at 0.80 and α = 0.05, a minimum of 4 mice in each group was needed.
Raw files were processed with Proteome Discoverer 2.2 (Thermo Scientific) using the default MS3 SPS method 
with the following modifications for importation into Scaffold Q+ . Target Decoy PSM validator was used instead 
of Percolator and Maximum Delta Cn was set to 1. All MS/MS samples were analyzed using Sequest HT to search 
all mouse sequences from Uniprot (https://www.uniprot.org/proteomes/UP000000589) and 110 common lab-
oratory contaminants (http://thegpm.org.crap) plus an equal number of reverse decoy sequences assuming the 
digestion enzyme trypsin17. Sequest-HT was searched with a fragment ion mass tolerance of 0.20 Da and a parent 
ion tolerance of 10.0 PPM. Carbamidomethyl of cysteine and TMT10 plex of lysine were specified in Sequest-HT 
as fixed modifications17. Oxidation of methionine and acetyl of the n-terminus were specified in Sequest-HT as 
variable modifications.
Scaffold Q+ (version Scaffold_4.9.0, Proteome Software Inc., Portland, OR) was used to quantitate Label 
Based Quantitation (iTRAQ, TMT, SILAC, etc.) peptide and protein identifications. Peptide identifications were 
accepted17 with a decoy false discovery rate (FDR) cutoff of less than 0.2%. Protein identifications were accepted 
if they could be established with at least 2 unique identified peptides. Proteins that contained similar peptides 
and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsi-
mony. Proteins sharing significant peptide evidence were grouped into clusters20. Channels were corrected as 
described in the supplementary text21. Normalization was performed iteratively (across samples and spectra) 
on intensities, as described in Statistical Analysis of Relative Labeled Mass Spectrometry Data from Complex 
Samples using ANOVA22. Medians were used for averaging. Spectra data were log-transformed and weighted by 
an adaptive intensity weighting algorithm. Of 80801 spectra in the experiment at the required thresholds, 79849 
(99%) were incorporated into the quantitation and 4109 proteins were detected in 3700 clusters with 6 decoys 
(FDR 0.1%). 477 proteins were found to be differentially expressed (Supplemental Table 1), of which 302 proteins 
had a minimum fold change of 1.2 (Supplemental Table 2). All the analysis was carried out using the information 
from the 302 differentially expressed proteins (0.3% FDR) which show ≥[1.2]-fold change.
26S proteasome activity assay. Briefly, pulverized liver samples (20 mg aliquot) were homogenized in 
26 S proteasome lysis buffer (50 mM Tris, 150 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic 
acid (EDTA), 5 mM magnesium chloride (MgCl2) [pH 7.5]) with a hand-held Potter-Elvehjem homogenizer. The 
supernatant containing the proteasomes were separated after centrifugation at 12,000 xg for 15 min at 4 °C and 
were quantified and diluted to 1 μg/μL concentration with proteasome lysis buffer. The β5 (chymotrypsin-like), 
β2 (trypsin-like) and β1 (caspase-like) activities were assayed using 20 µg of protein. The assays were carried out 
in a total volume of 100 µL per well in a black 96-well plate. The adenosine triphosphate (ATP)-dependent 26 S 
assays were performed using 100 μM ATP in the absence and presence of a specific proteasome inhibitor: 10 μM 
bortezomib (β5 activity) and 100 μM bortezomib (β1 and β2 activities). Specific fluorescence-tagged substrates 
for each proteasomal β subunits (Enzo Life Sciences, NY, USA): Z-LLE-AMC for β1, Boc-LSTR-AMC for β2 and 
Suc-LLVY-AMC for β5 were used to initiate the reaction [27–30]. Proteasomal activities were measured at an 
excitation wavelength of 390 nm and an emission wavelength of 460 nm using a Fluoroskan Ascent fluorometer 
(Thermo Electron, MA) for every 15 min up to 120 min. Controls to validate the inhibitors used for these exper-
iments are shown in Supplemetary Fig. 1, and more extensive details about the proteasome assays have been 
previously published23.
Immunoproteasome activity. 20 μg of liver samples from ibuprofen-treated and control animals were incu-
bated with immunoproteasome buffer (50 mM Tris, 5 mM MgCl2, 20 mM potassium chloride (KCl), 1 mM DTT 
(freshly added), pH 7.5), and inhibitor or an equal volume of dimethyl sulfoxide (DMSO) for 20 min at room tem-
perature. The specific inhibitors for β5i 20 µM ONX-0914 (Abmole Bioscience Inc., Houston, TX, Cat. No. M2071) 
and for β1i 50 µM bortezomib was used to evaluate the specificity of the assay. The 25 µM fluorogenic substrates 
ANW-R110 (AAT Bioquest, Inc, CA) for β5i and (Ac-Ala-Asn-Trp)2-R110 (AAT Bioquest, Cat. No. 13455) 
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for β1i were used to initiate the reaction. The fluorescence intensity was measured every 5 mins for 60 min at an 
excitation of 498 nm and an emission of 520 nm at 37 °C in a Tecan Infinite M1000.
Catalase activity assay. 10 µg of mice liver was homogenized in 1.15% KCl using a Dounce homogenizer. 
The samples were centrifuged at 12,000 rpm for 15 minutes. The supernatant was extracted and diluted with 
50 mM phosphate buffer pH 7.0. The colorimetric assay to measure catalase activity in liver samples was done by 
using Sigma-Aldrich Catalase Assay Kit (Cat. CAT100). This assay in the presence of hydrogen peroxide (H2O2) 
and horseradish peroxidase (HRP) uses a substituted phenol (3,5-dichloro-2-hydroxybenzenesulfonic acid) that 
combines with 4-aminoantipyrine to form a red quinoneimine dye. All solutions were prepared as instructed by 
the manufacturer. Briefly, this assay measured the H2O2 substrate that remains after the catalase action. In first 
step, catalase via its catalytic pathway converted H2O2 to water and oxygen, and the reaction was stopped using 
sodium azide. Next, a small volume of reaction mix is then analyzed for the amount of H2O2 remaining by a 
colorimetric method. The absorbance was measured using a spectrophotometer at 520 nm, and the actual con-
centration was measured using Beer’s Law: [H2O2] (mM) = A240/0.0436.
Hydrogen peroxide (H2o2) assay. H2O2 assay was performed using Sigma Aldrich Fluorimetric Hydrogen 
Peroxide Assay Kit, (Cat. # MAK165). All steps were carried out as per manufacturer’s instructions. The assay is 
based on the peroxidase substrate that reacts with H2O2 to generate a red fluorescent product that can be analyzed 
by a fluorescent microplate reader. Briefly, controls, standards, and samples were added to the wells followed by 
the addition of a master mix that contains red peroxidase substrate, peroxidase and assay buffer. The plate was 
incubated for 15 minutes at room temperature protected from light. The fluorescence intensity was measured at 
excitation = 540 and emission = 590 nm.
Western blotting. Sample preparation. Pulverized liver tissue (20 mg) was homogenized in ice cold 1x 
RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate 
(SDS), pH 8) using a glass dounce homogenizer. The homogenates were centrifuged at 12,000 xg for 15 min at 
4 °C. The supernatants were separated and quantified using the BCA protein assay (Bio-Rad, Cat. #500–0119) 
and were diluted to equal protein concentrations. Liver samples were then mixed with 4X Laemmli sample buffer 
(8% SDS, 40% glycerol, 0.4% bromophenol blue, 240 mM Tris, pH 6.8) with freshly added β-mercaptoethanol and 
were heated for 5 mins at 95 °C.
Electrophoresis and western blotting. Equal amounts of protein (20 µg) were separated on 4–20% 18-well 
TGX precast gels (Cat. # 567–1094, Bio-Rad) and were transferred to a nitrocellulose membrane (Trans-Blot 
Turbo Midi Nitrocellulose, #170–4159, Bio-Rad) using the Trans-Blot Turbo Transfer System (Cat # 170–4155, 
Bio-Rad). The membranes were then stained with Ponceau S and imaged to serve as a loading control for total 
protein normalization of Western blots. Thereafter the membrane was blocked with 3% nonfat dry milk (NFM) 
(Cat. # 170–6404, Bio-Rad) in Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, pH 7.5) containing 0.05% 
(wt/vol) Tween 20 (TBST) at room temperature. The membranes were then incubated overnight at 4 °C with 
the following 14 primary antibodies diluted to 1:2000 in 1% TBST: mouse anti-CYP1A2 (sc-53614), mouse 
anti-PFK-1 (sc-166722), mouse anti-fatty acid synthase (A-5) (sc-55580), mouse anti-PKLR (sc-133222), mouse 
anti-GSTM1 (sc-517262), mouse anti-CROT (H-1)(sc-365976), mouse anti-PROHIBITIN 2 (A-2) (sc-133094), 
mouse anti-ATP5F1 (C-12) (sc-514419), mouse anti-CYP4A1(clo1) (sc-53248), mouse anti-PKM (C-11) (sc-
365684), mouse anti-GSTT2 (D-1) (sc-514667), mouse anti-FAAH (27-γ) (sc-100739), mouse anti-17-βHSD2 
(E-7) (sc-374150), mouse anti-GSTA1/2/5 (E-6) (sc-398714), mouse anti-ETFDH (D-2) (sc-515202), mouse 
anti-LFABP (C-4) (sc-374537), mouse anti-LMP2,β1i (A-1) (sc-271354, LOT#B1611), mouse anti-MECL-
1(71P6) β2i (sc-130295) (all from Santa Cruz), mouse anti-β5i (1:2000, custom made by Abgent), and rabbit 
anti-PSMA6 (1:20,000; Epitomics), The membranes were washed three times in TBST for 5 mins each and were 
incubated at room temperature for 1 hr with horseradish peroxidase conjugated rabbit anti-mouse or anti-rabbit 
IgG secondary antibody (Sigma-Aldrich, anti-mouse Cat. # A9044, anti-rabbit Cat. # A0545) diluted 1:10,000 in 
1% TBST. Blots were subsequently washed three times with 1X TBST for 5 mins each and developed using a com-
mercial chemiluminescent reagent (Clarity, Bio-Rad-170–5061) and imaged using the ChemiDoc MP (Bio-Rad). 
All incubation steps carried out at 4 °C or RT were done with gentle shaking. The quantification of blots was done 
by using Image Lab 5.0.
Statistical analysis. A summary of the number of samples used for the different experiments in these studies 
is shown in Supplemental Table 3.
For proteomics. Differentially expressed proteins were determined by applying Permutation Test with unad-
justed significance level of p < 0.05 corrected by the Benjamini-Hochberg procedure to reduce the FDR 
(p < 0.00674 after using Benjamini-Hochberg procedure).
For western blotting and biological assays. Results are expressed as mean ± standard deviation (SD) from at least 
three independent experiments. The comparisons between groups were performed using the Student’s t-test or 
one-way ANOVA. P values of <0.05 were defined as statistically significant.
Results
Proteomic profiling of male mice liver with quantitative 10-plex TMT LC-MS/MS showed significant differences 
between 7-day vehicle and ibuprofen treated mice livers. To our knowledge, this is the first report of proteomic 
profiling of mice liver treated with ibuprofen.
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Metabolic processes. The quantitative data obtained from mass spectrometry were analyzed using Panther 
program (http://www.pantherdb.org/about.jsp). The data revealed that when differentially expressed proteins 
were grouped by biological process, proteins associated with metabolic processes (GO:0008152) were the largest 
group of proteins that were altered (32.4%) in male ibuprofen-treated mice (Fig. 1). The other major biological 
process with the most proteins altered was cellular processes (GO:0009987) (Fig. 1). Based on molecular func-
tion, the comparison between the control and the ibuprofen treated mice livers showed that around 62.7% of the 
altered proteins were associated with catalytic activity (GO:0003824) (Fig. 1). Using the Panther Go-Slim program 
option, twenty-three biological processes showed a P-value of <0.001 and an FDR of <0.5% for over or under-
represented differentially expressed proteins (Table 1). These processes included fatty acid, carbohydrate, steroid, 
coenzyme, acyl-CoA metabolic processes, respiratory electron transport chain, G protein-coupled receptor 
pathway, and cell surface receptor signaling.
Proteasome dysfunction. The proteomic data suggested that that the level of the relatively low abundant 
proteasome subunit beta type-8 (PSMB8) (β5i) was decreased in ibuprofen treated male mice (Supplemental 
Table 1). During stress conditions, the constitutive proteasome β1, β2 and β5 subunits of 20 S proteasome are 
replaced by β1i, β2i, and β5i immunoproteasome counterparts24–26. Western blotting data showed that the expres-
sion levels of β5i immunoproteasome subunit was significantly decreased in ibuprofen treated male livers, con-
sistent with the proteomic data (Fig. 2A,B). However, β5i was significantly increased in ibuprofen treated female 
livers relative to control (Fig. 2C). The β1i subunit expression was considerably elevated in ibuprofen treated 
female livers but not in males whereas no change was observed in the levels of β2i expression in both male and 
female livers (Fig. 2B,C). The expression levels of PSMA6 (20S catalytic core subunit) in the ibuprofen treated 
male livers was significantly elevated relative to controls whereas no change was observed in female mice liv-
ers treated with ibuprofen and controls (Fig. 2B,C). Since changes in proteasome activity are suggested to be 
associated with various pathological conditions including aging, cardiac and neurodegenerative diseases27–29, we 
investigated the effects of ibuprofen on the proteasome and immunoproteasome activities. The β1 (caspase-like) 
proteasome activity was significantly decreased in ibuprofen treated male livers while significantly increased in 
ibuprofen treated female livers compared to control animals (Fig. 2D,E). The β2 (trypsin-like) activity was found 
to be significantly elevated in male livers, and equally significant (0.050) in ibuprofen-treated female livers relative 
to normal control livers (Fig. 2D,E). The β5 (chymotrypsin-like) activity was significantly decreased in ibuprofen 
treated female livers and showed a trend toward decrease (p = 0.085) in ibuprofen treated male livers (Fig. 2D,E). 
No change in immunoproteasome activities was observed in ibuprofen treated male and female livers compared 
to normal control livers (Fig. 2F,G).
To further investigate if ibuprofen altered proteasome function enough to change the levels of the ubiquiti-
nated and oxidized proteins, liver lysates were probed with anti-ubiquitin and anti-DNPH antibodies. The levels 
of polyubiquitinated and free ubiquitin proteins remained unchanged in both ibuprofen treated male and female 
livers (Fig. 3A,B). However, the levels of oxidized proteins decreased in ibuprofen treated male livers but not in 
ibuprofen-treated female livers (Fig. 3A).
Figure 1. A pie chart depicting the proteomic analysis of control and ibuprofen-treated male mice liver. 
Biological processes associated with the differentially expressed proteins were shown using the PANTHER 
classification system.
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Energy production pathways. The proteomic data revealed that several proteins related to fatty acid 
metabolism and glycolytic pathway as well as other metabolic pathways were either upregulated or downregu-
lated in ibuprofen treated male mice liver compared to control. To better understand the underlying molecular 
mechanisms, validation of the expression levels of different proteins associated with different energy metabolic 
pathways was carried out using Western blotting and biochemical assays to determine altered pathways activities.
Fatty acid metabolism pathway. To validate the expression levels of proteins related to β fatty acid 
metabolism the total liver lysates from male and female mice were probed with several antibodies to investi-
gate the enzymes involved in fatty acid metabolism. The data suggests that all four proteins FAS (fatty acid syn-
thase), LFABP (liver fatty acid-binding protein), CROT (carnitine O-octanoyltransferase), and FAAH (fatty acid 
amide hydrolase) (Fig. 4B) were significantly upregulated in male livers, consistent with proteomic data (Fig. 4A), 
whereas only FAS and LFABP was upregulated in ibuprofen treated female livers (Fig. 4C).
Since nearly all the enzymes involved in both mitochondrial β oxidation and peroxisomal β oxidation were 
upregulated by ibuprofen (Fig. 5, Supplemental Fig. 3), we measured H2O2 levels in the liver (Fig. 4F,G). H2O2 are 
reactive oxygen species that is increased when peroxisomal β oxidation is increased, and functions both as intra-
cellular messenger and as a source of oxidative stress30. In mice livers treated with ibuprofen, H2O2 was found to 
be significantly increased by 1.56-fold in male and 2.75-fold in females (Fig. 4F,G). Increases in H2O2 may lead to 
increases in catalase activity, and we observed significantly increased catalase activity in ibuprofen treated male 
livers (Fig. 4D) as well as in female mice livers (Fig. 4E).
PANTHER GO-Slim Biological Process








fatty acid beta-oxidation 7 0.25 27.56 + 2.93E-08 7.94E-07
fatty acid metabolic process 26 2.23 11.67 + 4.67E-19 3.80E-17
lipid metabolic process 44 5.21 8.45 + 1.94E-26 4.75E-24
primary metabolic process 98 55.86 1.75 + 3.18E-09 1.11E-07
metabolic process 125 69.37 1.8 + 2.29E-13 1.40E-11
pentose-phosphate shunt 2 0.08 24.75 + 4.43E-03 3.28E-02
carbohydrate metabolic process 12 3.6 3.33 + 3.73E-04 4.33E-03
vitamin biosynthetic process 3 0.13 23.62 + 4.87E-04 4.95E-03
vitamin metabolic process 3 0.25 11.81 + 2.81E-03 2.14E-02
cellular amino acid biosynthetic process 11 0.72 15.37 + 6.58E-10 2.68E-08
cellular amino acid metabolic process 31 2.62 11.83 + 1.07E-22 1.31E-20
porphyrin-containing compound metabolic process 3 0.24 12.37 + 2.49E-03 1.96E-02
cellular amino acid catabolic process 8 0.66 12.16 + 7.43E-07 1.81E-05
acyl-CoA metabolic process 5 0.43 11.71 + 1.12E-04 1.61E-03
coenzyme metabolic process 12 1.25 9.62 + 1.34E-08 4.08E-07
cholesterol metabolic process 4 0.42 9.62 + 1.10E-03 1.03E-02
steroid metabolic process 14 1.42 9.86 + 6.07E-10 2.96E-08
lipid transport 6 0.84 7.12 + 2.89E-04 3.71E-03
respiratory electron transport chain 8 1.29 6.19 + 7.21E-05 1.17E-03
generation of precursor metabolites and energy 10 2.11 4.73 + 7.90E-05 1.20E-03
sulfur compound metabolic process 5 0.88 5.7 + 2.36E-03 1.98E-02
muscle contraction 7 1.26 5.56 + 3.77E-04 4.18E-03
phospholipid metabolic process 7 2.05 3.41 + 5.48E-03 3.82E-02
catabolic process 33 13.9 2.37 + 5.62E-06 1.25E-04
regulation of biological process 16 38.33 0.42 − 2.77E-05 5.20E-04
biological regulation 25 45.01 0.56 − 6.55E-04 6.39E-03
RNA metabolic process 6 17.73 0.34 − 1.75E-03 1.53E-02
nucleobase-containing compound metabolic 
process 17 31.29 0.54 − 5.07E-03 3.64E-02
G-protein coupled receptor signaling pathway 0 10.1 <0.01 − 6.12E-05 1.07E-03
cell surface receptor signaling pathway 4 19.96 0.2 − 2.65E-05 5.40E-04
signal transduction 17 33.43 0.51 − 1.41E-03 1.27E-02
cell communication 21 37.74 0.56 − 2.40E-03 1.95E-02
sensory perception of smell 0 8.07 <0.01 − 4.54E-04 4.82E-03
sensory perception of chemical stimulus 0 8.64 <0.01 − 3.09E-04 3.77E-03
Table 1. Biological processes in mice liver affected by ibuprofen treatment. Twenty-three biological processes 
showed a p value of <0.001 and an FDR of <0.5% for over or underrepresented differentially expressed proteins 
using the Panther program.
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Other enzymes involved in fat and drug metabolism. Since proteomic results showed that CYP4A10 (cytochrome 
P450 A10) and CYP4A14 increased by 1.74 and 3.03-fold in ibuprofen treated male livers and antibodies to these 
were unavailable, we determined the expression of CYP4A1 which has >90% sequence homology with CYPA10. 
Figure 2. Effects of ibuprofen treatment on 20S proteasome and immuno-proteasome expression levels and 
activities in mice liver. (A) Changes in level of 26S proteasome subunits (β1, β2 and β5) and immunoproteasome 
subunits (β1i and β5i) obtained by mass spectrometry. Western blots of proteasome levels (PSMA6, β1i, β2i and 
β5i) and total protein (used as loading controls) in (B) Male liver, and (C) Female liver. Value are mean ± SE;  
n = 4–6 per group. *p < 0.05. (D) 26S proteasome (β1, β2 and β5) activities of liver lysates from male mice. 
(E) 26S proteasome (β1, β2 and β5) activities of liver lysates from female mice. (F,G) β1i and β5i immune-
proteasome activities of male and female liver lysates. Value are mean ± SE; n = 6 per group. *p < 0.05.
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The expression levels of CYP4A1 was significantly increased, 17β-HSD2 (17β hydroxyl steroid dehydrogenase 
type 2) was decreased, and CYP4A2 (cytochrome P450 1A2) not statistically changed in ibuprofen treated male 
livers (Fig. 6B). In contrast, the levels of CYP4A1 was decreased and CYP4A2 and 17β-HSD2 were increased in 
female livers treated with ibuprofen (Fig. 6C), suggesting a gender-specific difference in mice liver. A summary of 
some of the data is shown in Fig. 5.
Glycolytic pathway. Validation of glycolytic pathway proteins using Western blotting showed that the expression 
levels of PKLR (pyruvate kinase, liver and RBC), and PFK-1 (Phosphofructokinases-1) was downregulated in 
male livers than controls (Fig. 6E) while levels of PKLR was upregulated in ibuprofen treated female livers sug-
gesting a gender-specific difference with respect to glycolytic pathway. However, no difference was observed in 
the levels of PFK-1 in female livers (Fig. 6F).
Mitochondrial proteins. Consistent with proteomic data (Supplementary Fig. 2A) expression levels of inner 
mitochondrial membrane proteins Prohibitin-2 and ETFDH (electron transfer flavoprotein dehydrogenase) 
were both increased in male livers (Supplementary Fig. 2B). ATP5F1 (mitochondrial ATP synthase 5F1) showed 
a small increase in the proteomic studies but showed a decrease by Western blotting. The levels of ATP5F1, 
Prohibitin-2 and ETFDH were significantly increased in female livers treated with ibuprofen (Supplementary 
Figure 2C).
Antioxidant defense system. During oxidative stress and other stress conditions increased levels of H2O2 
is associated with elevated production of antioxidant enzymes31. The proteomic data showed that various anti-
oxidant enzymes such as glutathione S-transferase theta 2 (GSTT2), glutathione S-transferase Mu 1 (GSTMI), 
and glutathione S-transferase alpha 1/2/5 (GSTA1/2/5) were upregulated in male mice livers treated with ibu-
profen compared to controls (Fig. 7A, Supplementary Table 1). To independently validate the results, the expres-
sion levels of GSTT2, GSTM1 and GSTA1/2/5 were analyzed by Western blotting. The expression of GSTM1 
and GSTA1/2/5 was significantly upregulated in ibuprofen-treated male livers consistent with the proteomic 
data (Fig. 7B). In female ibuprofen-treated livers only the expression of GSTA1/2/5 was upregulated (Fig. 7C). 
Although not statistically significant, a trend towards increased GSTT2 (male) and GSTM1 (female) expression 
was observed in ibuprofen treated groups relative to control groups (Fig. 7B,C).
Figure 3. Characterization of levels of polyubiquitination, free ubiquitins and oxidized proteins in male and 
female mice livers. Western blot of polyubiquinated, free ubiquitin levels and oxidized proteins in total liver 
lysates from mice (A) Male livers & (B) Female livers. Value are mean ± SE; n = 6 per group. *p < 0.05.
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Figure 4. Validation of expression levels of proteins related to fatty acid metabolism pathway in male and 
female mouse liver. (A) Changes in the level of proteins FAS (Fatty Acid Synthase), LFABP (Liver Fatty acid-
binding protein), CROT (carnitine O-octanoyltransferase), and FAAH (fatty acid amide hydrolase) obtained 
from mass spectrometry. Western blots and corresponding semi quantitative bar graphs for proteins, FAS, 
LFABP, CROT, and FAAH and total protein (used as a loading control) (B) Male liver and (C) Female liver. 
Value are mean ± SE; n = 4–6 per group. *p < 0.05. Characterization of antioxidant catalase activity and 
hydrogen peroxide levels in control and ibuprofen-treated mouse livers. (D), (E) Catalase activity in male and 
female mouse liver. (F), (G) Relative hydrogen peroxide (H2O2) levels of male and female liver lysates. Value are 
mean ± SE; n = 5 per group. *p < 0.05.
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Discussion
It is well acknowledged that high dose and long term use of NSAIDs are associated with adverse effects that 
include cardiac, gastrointestinal, renal and hepatotoxicity32,33. The investigation of male mice liver using mass 
spectrometry suggests that even moderate dosages of ibuprofen treatment affect various critical cellular pathways. 
Since liver is a major player in metabolism, this approach also provides mechanistic quantitative information 
on the molecular pathways that are affected by drug toxicity34. Various NSAIDs such as bromfenac, benoxapro-
fen and lumiracoxib were withdrawn from the market due to severe hepatotoxicity35,36. The incidence rate of 
drug-induced liver injury in outpatients in France was found to be fourteen per 100000 patients37. However, this 
is considered an underestimation as it will be unlikely to be detected in smaller clinical trials, and a more recent 
study in 2010 found that NSAIDs including ibuprofen (odds ratio of 2.24, 95% confidence interval (CI) = 1.99–
2.52) increased the risk of hospitalization due to acute hepatitis (odds ratio 2.13, 95% CI = 2–2.18)35. The fre-
quency of drug-related hepatic injuries, including from NSAIDs, was found to be different in Spain and France 
suggesting that several factors besides the NSAIDs, such as drug use patterns and/or genetic and environmental 
factors, may be important36.
Upadhyay et al., showed that ibuprofen induced proteasome dysfunction, mitochondrial-mediated apoptosis, 
and cell death in A549 and/or Cos-7 cells38. However, the cell death, proteasome inhibition and apoptosis were 
observed using 1 mM ibuprofen, which is significantly higher than the peak ibuprofen concentrations found in 
human blood (58.4 µg/mL or 283.09 µM) after high doses of ibuprofen39, and as such may not be physiologically 
relevant. The proteomic results suggested that the immunoproteasome subunit β5i was decreased in livers from 
ibuprofen treated male mice and Western blotting and proteasome assays suggest gender-specific differences with 
respect to proteasome and immunoproteasome activities. The proteasome is part of the ubiquitin proteasome 
system (UPS), which is critical for protein quality control and is the main intracellular degradation pathway 
that eliminates polyubiquitinated misfolded and oxidized proteins by a multi-complex 26 S proteasome16,17,24,40. 
The 26S mainly degrades polyubiquitinated proteins in an ATP dependent manner and contains caspase-like, 
trypsin-like and chymotrypsin-like proteolytically active sites in the β1 (PSMB6), β2 (PSMB7), and β5 (PSMB5) 
subunits of the 20S core24,41. On induction with interferon-γ (IFN-γ), the constitutive β1, β2 and β5 subunits 
of 20S proteasome are replaced by catalytically active inducible β1i (PSMB9), β2i (PSMB10) and β5i (PSMB8) 
subunits referred as the immunoproteasome24,25. The immunoproteasome plays an important role in degrading 
oxidized proteins, preventing protein aggregation, cytokine production, antigen presentation and T cell differen-
tiation, and survival24,42.
The expression of the immunoproteasome β5i, which is important for the degradation of oxidized proteins 
under stressful conditions, was decreased in ibuprofen treated male livers relative to controls whereas it was 
Figure 5. Schematic diagram showing the changes in the levels and expression of enzymes involved in the 
glycolytic and fatty acid pathways in ibuprofen treated male and female mice livers. Abbreviations: PFK-1 
(Phosphofructokinases-1); PKLR (pyruvate kinase, liver and RBC); FAS (Fatty acid synthase); LFABP (Liver 
Fatty acid-binding protein); FAAH (fatty acid amide hydrolase); CROT(carnitine O-octanoyltransferase); 
CYP4A1(Cytochrome P450 4A1), ATP(Adenosine triphosphate); CYP1A2 (Cytochrome P450 1A2); TCA 
(tricarboxylic acid cycle).
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Figure 6. Determination and validation of expression levels of proteins related to fatty acid metabolism and 
glycolytic pathways in mouse liver. Changes in level of CYP4A10 (Cytochrome P450 4A10), 17β-HSD2 (17β 
hydroxysteroid dehydrogenase type 2), and CYP1A2 (Cytochrome P450 1A2) obtained by mass spectrometry 
(A). Western blots and corresponding semi quantitative bar graphs for CYP4A1, 17β-HSD2, and CYP1A2 
(Cytochrome P450 1A2) and total protein (used as a loading control). (B) Male liver and (C) Female liver. Value 
are mean ± SE; n = 4–6 per group. *p < 0.05. (D) Proteomic analysis and Western blots of proteins, PKLR 
(pyruvate kinase, liver and RBC), and PFK-1 (Phosphofructokinases-1), total protein (used as a loading control) 
and corresponding semi- quantitative bar graphs are shown for (E) male mice liver, and (F) female mice liver. 
Value are mean ± SE; n = 4–6 per group. *p < 0.05.
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increased in female mice livers in ibuprofen treated group. Despite the decrease in β5i expression in male livers 
and increased expression of β5i and β1i in female livers, the 26S β5i and β1i immunoproteasome activities remain 
unchanged in both ibuprofen treated male and female livers. Altered proteasome function is typically associated 
with increased levels of oxidized proteins and these possibilities were investigated in both male and female livers. 
The levels of oxidized proteins decreased in ibuprofen treated male livers compared to controls, while not signif-
icant, a trend towards the increase in levels of oxidized proteins (P = 0.086) was observed in ibuprofen-treated 
female livers relative to controls. A substantial decrease in β1 proteasome activity and β5i expression suggest 
altered proteasome functions in male livers. The elevated expression of 20S proteasome (increased PSMA6), 
which play an important role in the elimination of oxidized proteins, might be one of the mechanisms that 
account for reduced levels of oxidized proteins in male livers. However, in female livers increased β1, β1i and β5i 
expression, as well as a trend towards the increase in proteasome activities (β2, β1i, β5i) and β2i expression, sug-
gest that ibuprofen activated a compensated stress response in female livers as a mechanism to adapt to various 
stressors. It has been previously documented that increased oxidative stress regulates proteasome and immuno-
proteasome functions43. Altogether these results suggest that ibuprofen causes proteasome dysfunction in both 
mice genders, male mice respond differently than female mice with respect to proteasome function.
Figure 7. Effect of short-term ibuprofen treatment (7 days) on levels of oxidative-stress related proteins in 
control and ibuprofen-treated mouse livers. Change in levels of protein associated with oxidative stress, GSTT2 
(Glutathione S-transferase theta-2), GSTMI (Glutathione S-transferase mu 1), and GSTA1/2/5 (Glutathione 
S-transferase alpha 1/2/5) obtained by mass spectrometry (A). Western blot analysis was performed to 
determine the expression levels of protein associated with oxidative stress, GSTT2, GSTMI, and GSTA1/2/5 
in (B) Male mouse livers, and (C) Female mouse livers. Band signal intensities were analyzed by Image 
Lab® Software Version 12 and normalized with intensities obtained from loading control after staining with 
commercial Ponceau S for total protein. Value are mean ± SE; n = 4–6 per group. *p < 0.05.
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Proteins involved in antioxidant defense system. Mass spectrometry data showed that various anti-
oxidant enzymes such as GSTT2, GSTM1 and GSTA1/2/5 that helps to eliminate toxic metabolites generated 
by oxidative stress were upregulated in response to ibuprofen treatment in male mice livers than controls. The 
expression levels of GSTM1 and GSTA1/2/5 (significant) was higher in ibuprofen-treated male livers. Similarly, 
in female ibuprofen-treated livers the expression of GSTA1/2/5 was upregulated significantly. GSTT2 (male) 
and GSTM1 (female) showed a trend toward higher levels relative to respective controls. Catalase activity, an 
important antioxidant activity, showed higher levels in both male and female livers. Increased levels of H2O2 
was observed in both ibuprofen treated male and female livers relative to controls. During oxidative stress and 
other stress, conditions increased levels of H2O2 is associated with elevated production of antioxidant enzymes 
as a defense mechanism31 that explains the upregulation of anti-oxidant pathways in both male and female livers 
treated with ibuprofen. Also, the glutathione system plays regulatory role to maintain redox state of the cell44.
Proteins involved in energy metabolism. Mass spectrometry showed that proteins associated with met-
abolic processes are the largest group of differentially expressed proteins that occur in response to ibuprofen treat-
ment in male livers relative to controls. Western blotting showed that two of the three key enzymes involved in 
regulating glycolysis, pyruvate kinase L/R-type (PKLR) and phosphofructokinase 1 (PFK-1), were downregulated 
in male livers compared to controls. In contrast, PKLR was upregulated while no difference in the levels of PFK-1 
was observed in ibuprofen treated female livers. PKLR is an enzyme responsible for catalyzing the conversion 
of phosphoenolpyruvate and adenosine triphosphate (ATP) to pyruvate and ATP in glycolysis45. PFK catalyzes 
the rate-limiting phosphorylation of fructose-6-phosphate to fructose-1,6-diphosphate. Downregulation or defi-
ciency of pyruvate kinase leads to ATP depletion which in turn affects cell viability as well as accumulation of the 
glycolytic intermediates (2,3-diphosphoglycerate (2,3-DPG) that eventually leads to impaired glycolytic flux46. In 
isolated perfused rat livers mefenamic acid was reported to stimulate glycolysis, oxygen uptake, glycogenolysis 
and fructolysis47. PFK null mice were characterized by reduced lifespan, exercise intolerance and progressive 
cardiac hypertrophy48. Thus, the lower expression of PKLR and PFK-1 suggest that the ibuprofen affects metab-
olism and altered hepatic glucose metabolism in male mice. The upregulation of PKLR in female livers suggests 
accelerated glycolysis as an adaptive response to compensate for the depletion of ATP against oxidative stress.
Differential changes in PKLR in males (decreased) and females (increased) could have significant functional 
consequences in liver since glycolytic inhibition (such as by decreases in PKM2) has been suggested to promote 
the pentose phosphate pathway to generate higher levels of NADPH. NADPH is important in recycling oxidized 
glutathione and provides the reducing power needed for protein-based antioxidant systems49. ATP5F1 is part of 
the ATP synthase complex which generates ATP. ATP5F1 was reduced in male mice and increased in female mice 
compared to controls. In some cell types reduced ATP levels have been found to promote oxidative stress50. The 
electron transport chain is also a major site for superoxide production51. These results support several publica-
tions which suggest that oxidative stress is higher in male rats than female rats52,53.
A deficiency in cellular ATP has been suggested to cause several diseases54. In a mouse model of Leigh syn-
drome caused by a deficiency in a component of complex I, the levels of ATP were observed to dictate disease 
severity and neuronal death55. Intracellular ATP concentrations have also been shown to be important in intra-
cellular protein degradation with the proteasomal activity being regulated by ATP levels56. Importantly, impaired 
bioenergetics affects the redox balance of a cell57. ROS can also induce bioenergetic changes in cells and tissues, 
such as in liver where ROS induced changes in glucose and lipid metabolism58.
The mass spectrometry data also suggest that other metabolic pathways are affected, and these include path-
ways previously reported and summarized by Porter et al.59, such as the pentose phosphate shunt and the electron 
transport chain. Evidence for NSAIDs altering other pathways such as cholesterol60, and vitamin61 metabolic 
pathways all support the proteomic data. Other pathways that were found to be affected by NSAIDs that were not 
previously reported include steroid, phospholipid, sulfur compound, and amino acid metabolic pathways.
Proteins involved in fatty acid metabolism. Proteins involved in fatty acid biosynthesis. Glucose and 
fatty acids are metabolized in the liver and regulate whole-body energy homeostasis7. At high glucose levels, 
glycolysis is dominant and glycolytic intermediates and products are utilized to generate ATP as well as lipids 
and amino acids. During energy deprivation (low glucose levels), hepatocytes switch from glycolysis to fatty 
acid β oxidation for energy production7. Fatty acid oxidation depends upon the plasma concentration of free 
fatty acids and occurs in three subcellular organelles, the mitochondria and peroxisomes which carried out 
β-oxidation, whereas ώ-oxidation catalyzed by CYP4A1 takes place in endoplasmic reticulum62. FAS is an impor-
tant enzyme of fatty acid biosynthesis which in the presence of NADPH catalyzes the condensation of acetyl-CoA 
and malonyl-CoA to generate palmitic acid63. In normal healthy tissues, FAS is expressed at very low levels. 
High expression of FAS is correlated with molecular changes in various types of cancer cells including breast 
cancer64–66. Ibuprofen treatment stimulated higher expression of FAS in both male and female livers suggesting 
altered fatty acid metabolism.
Proteins involved in fatty acid oxidation. In liver, fatty acids are metabolized by two major metabolic pathways; 
they either undergo β-oxidation in mitochondria and peroxisomes to produce ATP for energy requirements or 
esterified to triglycerides to generate either lipoproteins to export or lipid droplets for storage. The short, medium 
and long fatty acid chains are oxidized in mitochondria whereas very long chain fatty acids are degraded by 
peroxisomes67. Kasuya et al. reported that various NSAIDs (diflunisal, enoxacin, salicylic acid, aspirin and oflox-
acin) and quinolone antimicrobial drugs have inhibitory effects on the medium chain acyl-CoA synthetase in 
mouse and bovine liver mitochondria68. LFABP regulates the lipid β-oxidation in mammalian liver and intestine 
and is correlated with various disease conditions including obesity, type 2 diabetes, insulin resistance, and fatty 
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liver disease in humans69,70. Elevated expression of LFABP in ibuprofen treated male and female livers together 
with increased levels of H2O2 (a byproduct of fatty acid β-oxidation) is indicative of increased fatty acid metab-
olism. FAAH is a membrane-bound enzyme that plays an important role in breaking endogenous fatty acid 
amides such as the endogenous cannabimimetic agent anandamide (AEA) and palmitoylethanolamide (PEA) 
(an anti-inflammatory agent)71. NSAIDs such as aspirin, ibuprofen, and indomethacin were reported to have 
inhibitory action on FAAH with different potencies. Ibuprofen was shown to attenuate the metabolism of AEA 
by FAAH in rat brain71. In this study ibuprofen significantly enhanced FAAH expression in male livers while no 
significant change in female livers was observed. Hence, gender-specific differences in fatty acid metabolism were 
observed in ibuprofen treated mice.
The CYP4A1 and 4A2 gene expression have been reported to increase with NSAIDs72–74. CYP1-4 enzymes 
play an important role in the oxidative metabolism of fatty acids, steroids, polycyclic aromatic hydrocarbons 
(PAHs), various drugs such as acetaminophen, caffeine, clozapine, phenacetin, clomipramine and naproxen, 
and other carcinogens and environmental pollutants73,74. When treated with ibuprofen male livers showed no 
change in CYP1A2 and elevated levels of CYP4A1 while female livers showed significantly elevated expression of 
CYP1A2 and lower expression of CYP4A1. The opposite effects of ibuprofen on CYP4A1 in male and female mice 
support previous publications which suggest that sex related differences occur with respect to drug metabolism 
and adverse reactions. Females have been shown to give a 1.5- to 1.7-fold higher risk factor for having adverse 
drug reactions than men75. Although the underlying mechanism for these gender effects is not known, some of 
the differences have been attributed to the levels of sex hormones and their receptors76. However, some studies 
suggest that estrous variability is no greater in females than the intrinsic variability in males77. Some of the sex dif-
ferences has also been linked to the expression of genes encoded by the X chromosome78. Other data also suggest 
that sex differences could occur at specific ages and in certain environments79. As such, we cannot assume that 
the sex related differences observed in this study is similar to what occurs at other ages. In these current studies, 
the sex-related differences observed may be partly due to sex-related differences in drug-metabolizing enzymes 
and drug transporters. The difference in the levels of CYP enzymes may also be related to the specific func-
tion of individual P450 enzymes and substrate specificity73. Moreover, oxidative stress and inflammatory factors 
can modulate CYPs transcription80. The increased oxidative stress in males could explain the lower expression 
of CYP4A1 in response to ibuprofen treatment. Although differential sex-related gene or protein expression of 
CYP4A1 has not been previously reported, many CYPs including CYP7A1 and CYP1B1 have been reported to 
show sex-related gene expression patterns81,82.
CROT is a carnitine acyltransferase that plays crucial roles in lipid metabolism and fatty acid β-oxidation83,84. 
Although localized to peroxisomes, CROT is essential for transport of medium and long length acyl-CoA chains 
from peroxisomes to the cytosol and mitochondria for further degradation83. The high expression of CROT in 
male (statistically significant) and female (trend to increase) livers suggest that it is possible that ibuprofen treat-
ment induces peroxisomal oxidation of medium and long chain fatty acids metabolism as a compensatory mech-
anism due to an overload of β-oxidation of fatty acids in mitochondria.
Other pathways proteins. 17β-HSD2 is a microsomal enzyme that catalyzes the oxidation of sex steroids 
testosterone and estradiol (E2) to less active ketones androstenedione and estrone (E1)85,86. It is reported that 
the inhibition of 17β-HSD2 in a in vivo monkey model and osteoporosis patients is beneficial to increase in E2 
and testosterone levels that facilitate reduction in bone resorption and maintenance of bone formation87. The 
gender-specific effect of ibuprofen in our study suggests that ibuprofen has more pronounced effect on female 
livers as higher 17β-HSD2 expression indicate more accumulation of sex hormone in females that will eventually 
lead to perturbed energy metabolism pathways. The age and sexual maturity of the mice used may also be impor-
tant in the levels of the enzymes involved in sex hormone biosynthesis and may be partly responsible for some of 
the observed gender specific differences.
Limitations of the study. Our study observed gender-specific ibuprofen-mediated effects on mice liver. 
However, since the proteomic profiling was only done on male mice, the liver proteins and pathways investigated 
by Western blotting and biochemical assays were limited only to proteins which were identified as differentially 
regulated in liver of male mice. It is likely that female-specific changes in protein expression also occur in ibupro-
fen treated livers and these changes were not investigated. The effects observed may also be age specific and could 
be significantly different in mice of different ages.
Conclusion
Mass spectrometry showed that moderate levels of ibuprofen given to healthy mice for seven days resulted in over 
300 proteins that were significantly altered when compared to control groups. Western blotting and biological 
assays showed that livers from male and female mice showed differences in the UPS, glycolysis and fatty acid 
metabolism. It is likely that many of the other pathways that were affected by ibuprofen also show gender differ-
ences, but these pathways were not investigated in this study. The data also suggests that ibuprofen affects pre-
viously unknown pathways such as amino acid, steroid and vitamin metabolism. Overall, our data indicate that 
moderate doses of ibuprofen can affect liver more significantly than previously reported and include proteasome 
dysfunction, increased levels of H2O2, impaired glycolytic pathways and altered fatty acid synthesis and oxidation. 
Although we expected similar differences between males and females with respect to ibuprofen treatment, com-
plex gender-specific ibuprofen-mediated effects were observed. These gender-specific effects may be important 
for the side effects of ibuprofen (such as increased risk of stroke) and more research is needed to investigate this 
possibility. The amounts of ibuprofen taken by males and females may need to be altered in the future. Although 
the published experimental data to support that males and females show important physiological differences that 
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affect the pathophysiology of many common diseases is increasing at a steady pace, very little gender-specific 
health care is utilized worldwide. Ultimately, gender should be considered in drug use, as the toxicity of some 
drugs is significantly different between women and men.
Data availability
Raw data, and Scaffold results are available from the MassIVE proteomics repository (MSV000083987) and 
Proteome Exchange PXD014279. All Western Blot raw data generated or analyzed during this study are included 
in this published article (Supplementary Figure 4). The datasets generated during the current study are available 
from the corresponding author on reasonable request.
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